/
CGON
$73.73+$0.80 (+1.10%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$6.3B
88M shares
52-week range
$23.65 – $75.50
97% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$35.58
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | $10.4M | $191.0K | $204.0K | $1.1M | $4.0M |
| Cost of revenue | $10.0K | $15.0K | $0 | $0 | $4.6M |
| Gross profit | $10.3M | $176.0K | $204.0K | $1.1M | −$607.0K |
| Gross margin | 99.9% | 92.1% | 100.0% | 100.0% | -15.0% |
| R&D | $18.3M | $29.0M | $45.8M | $82.1M | $116.6M |
| Operating income | −$12.6M | −$35.2M | −$55.4M | −$114.7M | −$190.8M |
| EBITDA | −$12.4M | −$35.4M | −$48.6M | −$88.0M | −$159.6M |
| Net income | −$12.8M | −$35.4M | −$48.6M | −$88.0M | −$161.0M |
| Net margin | -124.0% | -18556.5% | -23827.0% | -7729.5% | -3985.0% |
| EPS (diluted) | -0.28 | -0.66 | -1.02 | -1.41 | -2.08 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $11M | $-2.74 | $-2.92–$-2.45 | 12 |
| 2027 | $87M | $-2.84 | $-3.67–$-2.23 | 11 |
| 2028 | $458M | $-0.13 | $-1.70–$1.33 | 11 |
| 2029 | $961M | $3.28 | $1.71–$8.65 | 4 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
CG Oncology, Inc. Common stock
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
www.cgoncology.com- Employees
- 142
- IPO / List date
- Jan 25, 2024
- HQ
- DALLAS, TX
Held by traders on TradeandTell
No one on the platform currently holds CGON.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-06-30 | 46,100 | $1.2M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CGON yet.
